Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
REGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$642.00 - $1,211.20
Previous CloseN/A
Volume208.99K
Average Volume (3M)957.42K
Market Cap
$74.34B
Enterprise Value$74.99B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)17.9
Beta0.66
Next Earnings
May 01, 2025EPS Estimate
9.55Last Dividend Ex-Date
Feb 20, 2025Dividend YieldN/A
Share Statistics
EPS (TTM)38.28
Shares Outstanding107,507,540
10 Day Avg. Volume871,074
30 Day Avg. Volume957,416
Standard Deviation0.09
R-Squared0.00224
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.28
Price to Cash Flow (P/CF)14.80
P/FCF Ratio14.70
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.13
Enterprise Value/Ebitda15.59
Forecast
1Y Price Target
$958.60Price Target Upside37.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
---
Bulls Say, Bears Say
Bulls Say
DividendsRegeneron announced plans to start paying dividends, which contributed to a positive movement in the stock price.
Patent ProtectionDupixent's patent protection is expected to last longer than initially feared, securing the franchise's future revenue.
Stock RatingAnalyst recommends upgrading REGN shares from Market Perform to Outperform, indicating a strong positive outlook for the stock.
Bears Say
Biosimilar CompetitionAnalyst reiterates an underperform rating largely due to concerns about the impact of biosimilar competition on Eylea, which makes up about 50% of Regeneron revenues.
Earnings RiskConcerns exist that consensus earnings per share could be at risk from faster-than-expected Eylea erosion, impacting near-term performance.
Revenue ChallengesThe US Eylea franchise, accounting for approximately 42% of REGN’s sales, is experiencing a stock pullback primarily due to the challenges faced by the Eylea products.
---
Ownership Overview
1.94% Insiders
30.91% Mutual Funds
19.43% Other Institutional Investors
22.62% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $642.00 and its highest was $1211.20 in the past 12 months.
What is Regeneron’s market cap?
Regeneron’s market cap is $74.34B.
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is May 01, 2025 which is in 69 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Feb 04, 2025. The company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.282 by $0.788.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron pays a Notavailable dividend of $0.879 which represents an annual dividend yield of N/A. See more information on Regeneron dividends here
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is 9.55.
How many shares outstanding does Regeneron have?
Regeneron has 107,507,540 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $12.07 in its last earnings report, beating expectations of $11.282. Following the earnings report the stock price went up 4.53%.
Which hedge fund is a major shareholder of Regeneron?
Currently, no hedge funds are holding shares in REGN
---
Regeneron Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$958.60 (37.73% Upside)
$958.60 (37.73% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 972.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
―
20 days / 200 days
Momentum
-27.67%
12-Months-Change
Fundamentals
Return on Equity
15.95%
Trailing 12-Months
Asset Growth
14.25%
Trailing 12-Months
Company Description
Regeneron
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
---
REGN Company Deck
---
REGN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Regeneron's strong financial performance, driven by key products and a robust pipeline. However, challenges such as competitive pressure on EYLEA and increased R&D expenses were noted. The company's strategic capital allocation and pipeline advancements position it well for future growth.Read More>---
REGN Revenue Breakdown
44.87% EYLEA - U.S.
28.97% Sanofi
11.34% Bayer
4.11% Libtayo - U.S.
10.72% Other
---
REGN Stock 12 Month Forecast
Average Price Target
$958.60
▲(37.73% Upside)
Technical Analysis
Best Analysts Covering REGN
1 Year
1 Year Success Rate
29/42 ratings generated profit
1 Year Average Return
+15.74%
assigned a buy rating 24 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 69.05% of your transactions generating a profit, with an average return of +15.74% per trade.
---